The company has seen a 450% increase in demand for services since December. The expansion is expected to create numerous employment opportunities in the Exeter region, further stimulating the local economy.
Diagnexia UK Limited owned by Deciphex is the UK’s fastest-growing pathology diagnostics service provider. Yesterday (April 19th 2023), the company proudly celebrated the launch of its expanded facility at Exeter Science Park. The event was attended by local dignitaries, healthcare professionals, and business leaders.
The Exeter expansion highlights Diagnexia’s commitment to driving innovation in digital pathology and supporting local employment. The expanded facility will bolster Diagnexia’s capacity to provide rapid, accurate, and high-quality pathology services to multiple NHS trusts across the UK and in their facilities in Toronto and Chicago.
Pathology under pressure
Pathology is the hidden engine room of medical treatment and touches 95% of clinical pathways. However, Pathology is suffering chronic issues such as increasing delays in disease diagnosis, status and progression, falling pathologist numbers, increased demand for expertise, increasing diagnostic complexity and burgeoning patient wait times.
Streamlined workflows for labs
These pressures necessitate an innovative solution for optimal patient care. By digitising their pathology practices, labs can streamline their workflows, allowing them to take on larger caseloads while reducing turnaround times to improve patient care and outcomes.
The Deciphex clinical platform, Diagnexia, connects hospitals and laboratories to an international network of subspeciality expert pathologists, who can provide their expertise on clinical cases, ensuring the delivery of the highest quality of patient care for NHS Trusts and Healthcare services globally.
Turnaround times slashed to 2-3 days
Many of the bottlenecks suffered by labs are the result of traditional image analysis methods By digitising their pathology practices, labs can streamline their workflows, allowing them to take on larger caseloads while reducing turnaround times.
Connection to the Diagnexia network can reduce turnaround times from 2-3 months to 2-3 days.
Diagnexia is the complete remote diagnostic & consult service
Deciphex provides a fully digital, subspeciality-led, remote diagnostic & consult service. The Deciphex clinical platform, Diagnexia, connects hospitals and laboratories to an international network of subspeciality expert pathologists. Accessing this network of global expertise on clinical cases ensures the delivery of the highest quality of patient care for healthcare services.
Dr. Donal O’Shea, CEO of Diagnexia UK Limited, expressed his enthusiasm at the event, stating, “We are delighted to expand our presence in Exeter, a city that has consistently demonstrated its commitment to innovation and growth in the healthcare sector. Our new facility at Exeter Science Park will enable us to better serve our clients across the UK and beyond, while also providing valuable employment opportunities in the local community.”
Prof. Runjan Chetty, CMO of Diagnexia UK Limited, added, “The expansion of our Exeter facility is an exciting milestone for Diagnexia, as it enables us to further advance our mission of improving patient care through state-of-the-art digital pathology solutions. We look forward to continuing our collaboration with local healthcare professionals and organisations, such as Exeter Science Park, to drive innovation in the field.”
Tripled capacity at Exeter Accession Facility
The Deciphex Exeter Accession Facility is the central hub for the digitisation and upload of all biopsies to the Diagnexia Platform. The expansion of the Exeter accession facility along with the creation of 30 new jobs this year will triple the capacity at the facility to meet growing demand for services.
Current Deciphex clinical diagnostic turnaround times of less than 5 days strongly outpace typical turnaround times of 2-3 months. The facility’s increased capacity will further remove key delays in disease diagnosis, status, progression and patient care.
Attending the event, Steve Blunden, Head of Histopathology at University Hospitals Plymouth NHS Trust acknowledged the potential impact of the expansion on the regional healthcare community. “Diagnexia’s investment in Exeter and the South West is testament to the region’s growing reputation as a hub for innovation and excellence in healthcare. We look forward to the opportunities this expansion will bring, both for the local economy and for improved patient care in the region.”
Sally Basker, CEO of Exeter Science Park, added “We are very pleased that Diagnexia has chosen to join our emerging health and life sciences cluster at Exeter Science Park. We help innovative science-based companies to deliver extraordinary growth and so we are excited to see 450% growth opportunities opening up for Diagnexia with the promise of high value jobs, enhanced productivity and economic growth. We look forward to helping them on their journey.”
This expansion has been supported by the Heart of the South West Local Enterprise Partnership through the award of the European Regional Development Fund Inward Investment Support Grant Scheme to Deciphex.
